In vitro and in vivo antitumor activity of a novel immunomodulatory drug, leflunomide: mechanisms of action (Q42810119)

7 November 2017

In vitro and in vivo antitumor activity of a novel immunomodulatory drug, leflunomide: mechanisms of action (English)

1 reference

7 November 2017

Xu X

1

1 reference

7 November 2017

Shen J

2

1 reference

7 November 2017

Mall JW

3

1 reference

7 November 2017

Myers JA

4

1 reference

7 November 2017

Huang W

5

1 reference

7 November 2017

Blinder L

6

1 reference

7 November 2017

Saclarides TJ

7

1 reference

7 November 2017

Williams JW

8

1 reference

7 November 2017

Chong AS

9

1 reference

7 November 2017

language of work or name

English

0 references

publication date

1 November 1999

1 reference

7 November 2017

Biochemical Pharmacology

1 reference

7 November 2017

58

1 reference

7 November 2017

1405-1413

1 reference

7 November 2017

9

1 reference

Molecular genetics of human glioma.

7 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2899%2900228-2

Epidermal-growth-factor receptors in human bladder cancer: comparison of invasive and superficial tumours

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2899%2900228-2

Tyrphostins I: synthesis and biological activity of protein tyrosine kinase inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2899%2900228-2

Tyrphostins. II. Heterocyclic and .alpha.-substituted benzylidenemalononitrile tyrphostins as potent inhibitors of EGF receptor and ErbB2/neu tyrosine kinases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2899%2900228-2

Inhibition of insulin-dependent lipogenesis and anti-lipolysis by protein tyrosine kinase inhibitors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2899%2900228-2

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2899%2900228-2

From bench top to bedside

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2899%2900228-2

The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2899%2900228-2

Leflunomide interferes with pyrimidine nucleotide biosynthesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2899%2900228-2

Dihydroorotate dehydrogenase is a high affinity binding protein for A77 1726 and mediator of a range of biological effects of the immunomodulatory compound

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2899%2900228-2

Inhibition of Protein Tyrosine Phosphorylation in T Cells by a Novel Immunosuppressive Agent, Leflunomide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2899%2900228-2

Two activities of the immunosuppressive metabolite of leflunomide, A77 1726. Inhibition of pyrimidine nucleotide synthesis and protein tyrosine phosphorylation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2899%2900228-2

Inhibition of smooth muscle cell proliferation in vitro by leflunomide, a new immunosuppressant, is antagonized by uridine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2899%2900228-2

Inhibition of the epidermal growth factor receptor tyrosine kinase activity by leflunomide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2899%2900228-2

Inhibition of dihydroorotate dehydrogenase by the immunosuppressive agent leflunomide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2899%2900228-2

10.1016/S0006-2952(99)00228-2

7 January 2021

Identifiers

DOI

1 reference

7 November 2017

1 reference